<p>铁木药业公司（NASDAQ:IRWD - 获取免费报告）周四股价下跌了 5%。该股最低交易价为 3.57 美元，最后交易价为 3.5450 美元。在午盘交易中，约有 366,023 股被交易，较日均交易量 2,568,063 股下降了 86%。该股此前收盘价为 3.73 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对该股发表了看法。华尔街 Zen 在 8 月 9 日的报告中将铁木药业的评级从 “持有” 上调至 “强烈买入”。Zacks Research 在 11 月 4 日的研究报告中将铁木药业的评级从 “强烈买入” 下调至 “持有”。富国银行在 11 月 11 日的研究报告中将铁木药业的目标价从 1.00 美元上调至 3.00 美元，并给予该股 “等权重” 评级。最后，Weiss Ratings 在周一的研究报告中重新发布了对铁木药业的 “卖出（d）” 评级。一位股票研究分析师给予该股 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股的平均评级为 “持有”，平均目标价为 5.34 美元。</p>
<p><strong>阅读我们最新的铁木药业股票报告</strong></p>
<h2>铁木药业股票表现</h2>
<p>该公司的 50 日移动平均价格为 2.21 美元，200 日移动平均价格为 1.35 美元。该股市值为 5.7865 亿美元，市盈率为 22.30，贝塔值为 0.18。</p>
<p>铁木药业（NASDAQ:IRWD - 获取免费报告）最近在 11 月 10 日发布了季度财报。这家生物技术公司报告每股收益（EPS）为 0.24 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.15 美元。该季度的营业收入为 1.2206 亿美元，而一致预期为 7422 万美元。铁木药业的净利润率为 8.70%，股本回报率为负 15.17%。分析师预计铁木药业将在本财年发布 0.1 美元的每股收益。</p>
<h2>机构投资者对铁木药业的看法</h2>
<p>大型投资者最近调整了对该股的持有。Integrated Wealth Concepts LLC 在第三季度将其在铁木药业的持仓提高了 21.4%。Integrated Wealth Concepts LLC 目前持有 19,295 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了 3,406 股。McAdam LLC 在第一季度购买了铁木药业的新股份，价值约 40,000 美元。Vise Technologies Inc.在第三季度购买了铁木药业的新股份，价值约 39,000 美元。法国巴黎银行金融市场在第三季度将其在铁木药业的持仓增加了 83.2%。法国巴黎银行金融市场目前持有 34,331 股该生物技术公司的股票，价值 45,000 美元，此前在上个季度购买了 15,594 股。最后，华侨银行在第二季度购买了铁木药业的新股份，价值约 25,000 美元。</p>
<h2>铁木药业公司简介</h2>
<p>（获取免费报告）</p>
<p>铁木药业公司是一家医疗保健公司，专注于胃肠道（GI）产品的开发和商业化。它在美国、墨西哥、日本、沙特阿拉伯和中国以 LINZESS 的名称销售 linaclotide，这是一种用于治疗患有便秘型肠易激综合症或慢性特发性便秘的成人的鸟苷酸环化酶 C（GC-C）激动剂，同时在加拿大和欧洲国家以 CONSTELLA 的名称销售。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过铁木药业</li>
<li>商业服务股票投资</li>
<li>Wolfspeed 刚获得 6.98 亿美元的救助——这改变了一切</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>优步在达拉斯推出机器人出租车后获得华尔街最高评级</li>
<li>什么是认沽期权交易量？</li>
<li>投资者对 Box 的看法完全错误——这次由 AI 驱动的反弹刚刚证明了这一点</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在铁木药业吗？</h2>
<p>在你考虑投资铁木药业之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而铁木药业并不在名单上。</p>
<p>虽然铁木药业目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Ironwood医药

<p>Ironwood Pharmaceuticals 的股票下跌了 5%，至 3.5450 美元，交易量较平均水平下降了 86%。分析师的评级各不相同：华尔街 Zen 将评级上调至 “强力买入”，Zacks 将评级下调至 “持有”，Weiss Ratings 则给出了 “卖出” 评级。该股票的平均评级为 “持有”，目标价为 5.34 美元。最近的财报超出预期，每股收益为 0.24 美元，收入为 1.2206 亿美元。机构投资者已调整其持股情况，有些增加了持股比例。Ironwood 专注于胃肠道产品，旗下以 LINZESS 和 CONSTELLA 品牌营销 linaclotide</p>

<p>Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) dropped 5% on Thursday . The stock traded as low as $3.57 and last traded at $3.5450. Approximately 366,023 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,568,063 shares. The stock had previously closed at $3.73.</p>
<div class="lb-trans"><p>铁木药业公司（NASDAQ:IRWD - 获取免费报告）周四股价下跌了 5%。该股最低交易价为 3.57 美元，最后交易价为 3.5450 美元。在午盘交易中，约有 366,023 股被交易，较日均交易量 2,568,063 股下降了 86%。该股此前收盘价为 3.73 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 4th. Wells Fargo &amp; Company upped their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Ironwood Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and an average target price of $5.34.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股发表了看法。华尔街 Zen 在 8 月 9 日的报告中将铁木药业的评级从 “持有” 上调至 “强烈买入”。Zacks Research 在 11 月 4 日的研究报告中将铁木药业的评级从 “强烈买入” 下调至 “持有”。富国银行在 11 月 11 日的研究报告中将铁木药业的目标价从 1.00 美元上调至 3.00 美元，并给予该股 “等权重” 评级。最后，Weiss Ratings 在周一的研究报告中重新发布了对铁木药业的 “卖出（d）” 评级。一位股票研究分析师给予该股 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股的平均评级为 “持有”，平均目标价为 5.34 美元。</p>
</div><p><strong>Read Our Latest Stock Report on IRWD</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的铁木药业股票报告</strong></p>
</div><h2>Ironwood Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>铁木药业股票表现</h2>
</div><p>The company's 50 day moving average price is $2.21 and its 200-day moving average price is $1.35. The stock has a market cap of $578.65 million, a P/E ratio of 22.30 and a beta of 0.18.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 2.21 美元，200 日移动平均价格为 1.35 美元。该股市值为 5.7865 亿美元，市盈率为 22.30，贝塔值为 0.18。</p>
</div><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>铁木药业（NASDAQ:IRWD - 获取免费报告）最近在 11 月 10 日发布了季度财报。这家生物技术公司报告每股收益（EPS）为 0.24 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.15 美元。该季度的营业收入为 1.2206 亿美元，而一致预期为 7422 万美元。铁木药业的净利润率为 8.70%，股本回报率为负 15.17%。分析师预计铁木药业将在本财年发布 0.1 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对铁木药业的看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC lifted its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. McAdam LLC purchased a new stake in Ironwood Pharmaceuticals during the first quarter valued at about $40,000. Vise Technologies Inc. bought a new position in Ironwood Pharmaceuticals during the third quarter worth about $39,000. BNP Paribas Financial Markets increased its stake in shares of Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 15,594 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $25,000.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股的持有。Integrated Wealth Concepts LLC 在第三季度将其在铁木药业的持仓提高了 21.4%。Integrated Wealth Concepts LLC 目前持有 19,295 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了 3,406 股。McAdam LLC 在第一季度购买了铁木药业的新股份，价值约 40,000 美元。Vise Technologies Inc.在第三季度购买了铁木药业的新股份，价值约 39,000 美元。法国巴黎银行金融市场在第三季度将其在铁木药业的持仓增加了 83.2%。法国巴黎银行金融市场目前持有 34,331 股该生物技术公司的股票，价值 45,000 美元，此前在上个季度购买了 15,594 股。最后，华侨银行在第二季度购买了铁木药业的新股份，价值约 25,000 美元。</p>
</div><h2>Ironwood Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>铁木药业公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p>
<div class="lb-trans"><p>铁木药业公司是一家医疗保健公司，专注于胃肠道（GI）产品的开发和商业化。它在美国、墨西哥、日本、沙特阿拉伯和中国以 LINZESS 的名称销售 linaclotide，这是一种用于治疗患有便秘型肠易激综合症或慢性特发性便秘的成人的鸟苷酸环化酶 C（GC-C）激动剂，同时在加拿大和欧洲国家以 CONSTELLA 的名称销售。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Ironwood Pharmaceuticals</li>
<li>Business Services Stocks Investing</li>
<li>Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas</li>
<li>What is Put Option Volume?</li>
<li>Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过铁木药业</li>
<li>商业服务股票投资</li>
<li>Wolfspeed 刚获得 6.98 亿美元的救助——这改变了一切</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>优步在达拉斯推出机器人出租车后获得华尔街最高评级</li>
<li>什么是认沽期权交易量？</li>
<li>投资者对 Box 的看法完全错误——这次由 AI 驱动的反弹刚刚证明了这一点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在铁木药业吗？</h2>
</div><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资铁木药业之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而铁木药业并不在名单上。</p>
</div><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然铁木药业目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ironwood Pharmaceuticals（纳斯达克股票代码：IRWD）股价下跌 5% - 现在是卖出的时机吗？